...
首页> 外文期刊>Molecular Immunology >Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy
【24h】

Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy

机译:鉴定新型HLA-A * 24:02限制性腺病毒血清型11特异性CD8 + T细胞表位,用于过继免疫治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Subgroup B adenovirus serotype 11 (Ad11) occasionally causes fatal infections in immunocompromised patients. The present study describes a novel Ad11 epitope presented by HLA-A*24:02 that could be used for adoptive immunotherapy. Ten synthetic Ad11 hexon protein-derived nonamer peptides that bound to HLA-A*24:02 were selected by a computer algorithm and MHC stabilization assay. Stimulation of peripheral blood mononuclear cells from HLA-A*24:02+ donors with each of these synthetic peptides induced peptide-specific CD8+ T-cells for three peptides. Testing the reactivity of these peptide-specific CD8+ T-cells against various target cells confirmed that peptide TYFNLGNKF is naturally processed in Ad11-infected cells and is presented by HLA-A*24:02. Emergence of TYFNLGNKF-specific CD8+ T-cells coincided with the clearance of adenoviruses in a patient with Ad11 disease. Importantly, TYFNLGNKF-specific CD8+ T-cells were suggested to be not serotype cross-reactive. The novel HLA-A*24:02-restricted Ad11 epitope could be used for anti-Ad11 adoptive immunotherapy and to monitor immunity to Ad11 using MHC tetramers.
机译:B亚型腺病毒血清型11(Ad11)有时会在免疫受损的患者中引起致命感染。本研究描述了由HLA-A * 24:02提出的新型Ad11表位,可用于过继免疫治疗。通过计算机算法和MHC稳定化分析,选择了十个与HLA-A * 24:02结合的合成Ad11六邻体蛋白衍生的九聚体肽。用这些合成肽中的每一种刺激来自HLA-A * 24:02+供体的外周血单核细胞诱导了三种肽的肽特异性CD8 + T细胞。测试这些肽特异性CD8 + T细胞对各种靶细胞的反应性,证实肽TYFNLGNKF在Ad11感染的细胞中自然加工,并由HLA-A * 24:02呈现。 TYFNLGNKF特异性CD8 + T细胞的出现与Ad11病患者的腺病毒清除率相吻合。重要的是,建议TYFNLGNKF特异性CD8 + T细胞不是血清型交叉反应。新型的HLA-A * 24:02限制性Ad11表位可用于抗Ad11过继免疫疗法,并使用MHC四聚体监测对Ad11的免疫力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号